Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B4890d25b24b21ac51d6e19277b4d8bc6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B4890d25b24b21ac51d6e19277b4d8bc6 NCIT_P378 "NCI" @default.
- B4890d25b24b21ac51d6e19277b4d8bc6 type Axiom @default.
- B4890d25b24b21ac51d6e19277b4d8bc6 annotatedProperty IAO_0000115 @default.
- B4890d25b24b21ac51d6e19277b4d8bc6 annotatedSource NCIT_C2241 @default.
- B4890d25b24b21ac51d6e19277b4d8bc6 annotatedTarget "A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with mesmulogene ancovacivec may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells." @default.